--(BUSINESS WIRE)--SIRS-Lab GmbH is a biotechnology company focused on the identification of novel biomarkers and the development of in-vitro diagnostics for the early detection of bacterial causes of infection and the inflammatory/immunological host response in intensive care medicine as well as sepsis. Three programs for the development of clinical in vitro diagnostics are presently in progress. Using state-of-the-art methods of functional genomic and proteomic research, SIRS-Lab has successfully identified several biomarker candidates. SIRS-Lab started operations in April 2001, launched its first product line in May 2002 and has currently 30 employees.
